GAITHERSBURG, Md. & BOSTON–(BUSINESS WIRE)–Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing personalized yet off the shelf immunotherapies for cancer and infectious diseases, today announced the appointment of Anu Hoey as Chief Business Officer, responsible for leading business and corporate development.
“We are thrilled to welcome Anu to our team to help drive our strategic growth. Her business development experience and industry knowledge are a strong addition to Sensei as we prepare to grow our platform and pipeline in the coming months,” said John Celebi, CEO of Sensei Biotherapeutics. “With over 18 years of transactional and corporate expertise, Anu will be instrumental as we work to advance our pipeline and execute on our vision of establishing a new and disruptive class of immunotherapies.”